CEO Roundtable on Cancer 2020 Annual Report

www.ceoroundtableoncancer.org

CONVENER COLLABORATOR CATALYST ANNUAL REPORT | 2020

IN THE FIGHT AGAINST CANCER

CONVENER COLLABORATOR CATALYST

LETTER FROM THE CEO WELL-BEING: “How people think, feel and function at a personal and social level and how they evaluate life.”

Dear friends, For the CEO Roundtable on Cancer, 2020 was a year to refocus and apply new energy to areas where we can best impact cancer prevention, advancing treatment and survivorship.

We did this by: Broadening our focus on health to include well-being, which we define as how people think, feel and function at a personal and social level and how they evaluate life.

Accelerating the pace of our research programs despite the pandemic’s impact on our partners,

CONVENER COLLABORATOR CATALYST www.ceoroundtableoncancer.org

thanks to a full year of stable staffing in Project Data Sphere.

Identifying a future full of opportunities but needing additional company engagement through a refreshed Life Science Consortium and the newly formed Health and Well-being Consortium.

Thank you for your support in 2020, especially as you weathered your own challenges. We look forward to working side-by-side again in the coming year to tackle cancer in our organizations and communities.

We believe the power of bringing together action-oriented CEOs and their organizations to reduce the cancer burden in our communities will improve health for generations to come.

Best wishes for a healthy and successful 2021,

K. Andrew Crighton, MD Chief Executive Officer, CEO Roundtable on Cancer

1

CONVENER COLLABORATOR CATALYST

CONVENER COLLABORATOR CATALYST

THE MISSION

CONVENER

The CEO Roundtable on Cancer is a 501(c)(3) non-profit committed to being a Convener, Collaborator, and Catalyst in the fight against Cancer.

The CEO Roundtable on Cancer is growing. In 2020, our footprint spread to 35 states where a CEORT member company or Gold Standard accredited company were headquartered.

ACHIEVING TOGETHER WHAT CANNOT BE DONE ALONE

Research:

Health and well-being:

35 states have a CEORT member company headquarter (dark gold) or Gold Standard accredited company

We are a resource for and a contributor to the

With action-oriented chief executives, we work

headquarter (light gold).

global oncology research community through

together to improve cancer prevention, diagnosis,

Project Data SphereTM. We host an open-access

and treatment for employees, their families and

platform with aggregated oncology trial data from

their communities through the CEO Cancer Gold

biopharmaceutical companies, academic medical

StandardTM, our employer-led health and well-being

centers, and government organizations. We also

accreditation program.

New members in 2020: Alphanumeric Systems

Foundation Medicine Inc.

and Randy Trice, CEO.

and Brian Alexander, Chief Medical Officer.

convene oncology experts and collaborate across

BeiGene

Menarini Group

industry, academia, and government organizations

and John V. Oyler, Chairman, Co-Founder and CEO.

and Elcin Barker Ergun, CEO.

on research to catalyze discovery of urgently needed

Daiichi Sankyo Inc.

new treatments and help to make cancer trials faster, more effective, and less expensive.

and Ken Keller, President and CEO. 2

3

CONVENER COLLABORATOR CATALYST

CEO Roundtable on Cancer members

CONVENER COLLABORATOR CATALYST

CEO Roundtable on Cancer members

4

5

CONVENER COLLABORATOR CATALYST

CONVENER COLLABORATOR CATALYST

CONVENER Our annual meeting expanded to include workshops on health disparities, employee well-being, data sharing, and use of Artificial Intelligence to measure tumor progression.

A successful virtual FDA-PDS Symposium IX on Rare Cancer Registries in October provided guidance and suggested next steps for our research initiative on Registries.

Life Sciences Consortium COVID-19 Virtual Conference.

COVID-19 immediately affected the conduct of ongoing oncology clinical trials but it equally changed the way they will be conducted in the future, we learned from speakers at our online conference April 24 on “Maintaining Oncology Clinical Trial Integrity during the Covid-19 Pandemic.”

FDA - PDS Virtual Symposium IX, Rare Cancer Registries.

6

7

CONVENER COLLABORATOR CATALYST

CONVENER COLLABORATOR CATALYST

COLLABORATOR

COLLABORATOR The four research projects operated by Project Data SphereTM benefit from the counsel of scientists from industry, academia and government agencies.

CEO Roundtable on Cancer Founding CEO Bob Ingram connected us to the work of the U.S. President’s Cancer Panel on which he is a member.

At our annual meeting he shared insights about the Panel’s focus and plans.

Nationally recognized experts are advising us on

L. Michelle Bennett, PhD,

a refresh of the CEO Cancer Gold Standard™, our

Director, Center for Research

employer-led health and well-being accreditation

Strategy, National Cancer Institute.

program. The advisors helping us offer member companies the latest in thinking on employee

Otis Brawley, MD,

health and well-being are:

Bloomberg Distinguished Professor at Johns Hopkins University and a

David Shepperly, MD,

globally recognized expert in cancer

Executive Director Occupational Health,

prevention and control.

Chief Employee Health Officer and

School of Public Health at

Corporate Medical Director,

Johns Hopkins University.

One or more FDA staff participate as observers in

Women’s Hospital, MD Anderson Cancer Center,

the Steering Committee of each Research Program.

Duke University Medical Center and Duke Clinical

The senior FDA sponsor of this collaboration is

Research Institute.

Oncology Center of Excellence. Other collaborating

Ron Goetzel, PhD, Senior Scientist at the Bloomberg

Columbia University Medical Center, Brigham and

Paul Kluetz, Associate Director of the FDA

Bristol Myers Squibb.

Marcelo C. Targino, MD, MPH,

Government agency involvement:

agencies are the National Cancer Institute and European Medicines Agency.

Internationally recognized institutions:

Academia: Boston University School of Public Health, Massachusetts Institute of Technology, George Washington University School of Medicine & Health Sciences.

Dana -Farber / Harvard Cancer Center,

Johnson & Johnson.

8

9

CONVENER COLLABORATOR CATALYST

CATALYST

CONVENER COLLABORATOR CATALYST

CATALYST 14 companies celebrated 10 years of Gold Standard accreditation

The CEO Cancer Gold StandardTM is helping grow healthy communities and now benefits more than 7 million employees and their families.

Improving the health and well-being of our employees and their families is a priority for RTI International. By meeting the high standards of this initiative since 2010, we are working to help our employees prevent cancer and reduce the risk of other serious conditions, such as cardiovascular disease, obesity, and diabetes.

E. Wayne Holden, PhD President and CEO, RTI International

It’s an honor to be recognized for this accomplishment. The health and well-being of our employees is a top priority at UPMC. We’re committed to giving our patient and employees the knowledge, inspiration, and specialty care needed to address cancer or any illness.

Brian Durniok President, UPMC Chautauqua

At Susan G. Komen we are committed to doing everything we can to save lives and end breast cancer, and that starts with a workplace committed to the health of our team. We truly value our CEO Cancer Gold Standard accreditation, as it recognizes the value we place on promoting a healthy lifestyle and providing support to those facing a cancer diagnosis.

Paula Schneider President and CEO, Susan G. Komen

10

11

CONVENER COLLABORATOR CATALYST

CATALYST

CONVENER COLLABORATOR CATALYST

CATALYST The prestigious Gold Standard accreditation signifies to all that RWJBarnabas

At Moda, our mission is clear. We build healthy communities. And for us that

Health maintains a culture that encourages a healthy lifestyle for our

work begins at home. As CEO, I take great pride in the commitment made by

employees, our patients, and their families.

people across 10 years throughout our organization to ‘walk the talk’ in the

Barry H. Ostrowsky

fight against cancer.

Robert Gootee

President and CEO, RWJBarnabas Health

CEO, Moda Health

Our goal at Quest Diagnostics is to create a healthier world, and that begins

MassMutual has a strong commitment to personal health and well-being,

with the physical and mental health of our 47,000 employees. Employee health

ranging from our comprehensive wellness programs for our employees to our

strategy that fosters healthy behavior, regular screening and personalized

support for breast cancer awareness efforts and research across the US. As a

treatment can go a long way in lowering risks and improving outcomes from

long-time provider of insurance coverage to breast cancer survivors, we are

cancer and many other diseases. As we mark 10 years as a Gold Standard

proud to join the fight against cancer and promote healthy lifestyles that will

employer, we remain committed to doing our part to promote a cancer-free world.

help people lead long, enriching and fulfilling lives.

Steve Rusckowski,

Roger Crandall Chairman, President and CEO,

Chairman, Chief Executive Officer and President

Massachusetts Mutual Financial Group

of Quest Diagnostics At Goodmans, nothing is more important than the welfare of our people.

A top priority at MDU Resources Group is the safety and well-being of our

The Gold Standard is a way to demonstrate our commitment to the health of

employees. We seek every opportunity to promote good health practices

our employees by actively promoting cancer prevention and early detection.

among our team members.

As a family business, we believe we have an obligation to educate our team

David L. Goodin President and CEO, MDU Resources Group Inc.

members so they understand the link between lifestyle choices and cancer risks.

Adam Goodman President and CEO, Goodmans Interior Structures

12

13

CONVENER COLLABORATOR CATALYST

CATALYST

CONVENER COLLABORATOR CATALYST

CATALYST CPRIT is pleased to join other fine organizations around the country in

Cerner is honored to be recognized for the 10th year as the CEO Cancer Gold

adopting the CEO Cancer Gold Standard. Maintaining a culture that fosters

Standard as a commitment to the health and wellness of our associates and

healthy lifestyles are not only extended to our employees but are core tenets

their families. As a health care technology company, we’re committed to

of CPRIT’s mission in Texas.

working together each day to deliver and discover new innovations to help Wayne Roberts

improve health outcomes. Our innovative technology equips medical experts

CEO, CPRIT

with tools as they help their patients fight cancer and other chronic conditions. We’re pleased to be recognized alongside other organizations dedicated to the health of their employees.

Brent Shafer

To best prevent and treat cancer, infectious diseases, and other serious

Chairman and CEO, Cerner Corporation

health issues, we must work as a team devoted to wellness. AlphaMed Press remains committed to supporting and implementing the principles of the CEO Cancer Gold Standard. We emphasize workplace wellness as a vital

As a major employer and a health insurer, we’re committed to doing

part of our corporate culture and encourage other companies to proactively

everything we can to help our workforce prevent cancer, make sure they

invest in their employees’ well-being by embracing the Gold Standard.

have quality care and support for those diagnosed with cancer. That includes

Ann Murphy, PhD

mobile mammography, smoking cessation programs, onsite fitness centers,

President and CEO, AlphaMed Press

workplace health clinics, abundant fresh produce and community involvement.

At Blue Cross NC, our mission is to improve the health and well-being of our

As a leading health organization in our region, we want to be a strong

customers and communities and maintaining this accreditation reinforces

influence for better health and prevention, and there’s no better place to start

our ongoing progress towards this goal.

Tunde Sotunde MD, MBA, FAAP

than among our own employees.

David Flicek

President and CEO, Blue Cross, NC

Regional President and CEO, Avera McKennan Hospital and University Health Center 14

15

CONVENER COLLABORATOR CATALYST

CONVENER COLLABORATOR CATALYST

CATALYST

CATALYST

Bristol Myers Squibb obtained Global Gold Standard accreditation.

Project Data SphereTM is impacting cancer research through expanded use of its data platform and progress of its research programs.

Five new companies achieved Gold Standard accreditation:

TM

The PDS data platform has grown to offer data from oncology clinical trials involving more than 160,000 patient lives, more than 23,000 data downloads resulting in more than 90 publications in peer-reviewed journals.

Peer-reviewed Publications as of October 2020

80

Reporting about data on our platform

Non Small Cell Lung Cancer Pancreatic Cancer Other types

Peer-reviewed Publications

Lawton, Oklahoma

Colorectal Cancer Breast Cancer

91

Goodyear Tire and Rubber facility in

Related to Types of Cancers

Related to our Programs Prostate Cancer Dream Challenge Data Sharing Program Immune-related Adverse Event Program External Control Arms Program

11

16

Advocating for data sharing as on our platform

17

CONVENER COLLABORATOR CATALYST

CATALYST

THE FUTURE

Data Sharing Platform

selected lesions) and an enhanced measurement of

The platform has been enhanced to create a better

tumor burden based on the volumes of all lesions.

user experience for finding, accessing, and analyzing the datasets of interest. Further, the platform is now capable to host imaging data, real world data,

CONVENER COLLABORATOR CATALYST

Rare Tumor Registries

We are starting a three-year Campaign in 2021 to expand funding and relevance of the CEO Roundtable on Cancer with impact across the organization.

The Merkel Cell Carcinoma Registry is accruing patients at multiple academic research centers;

The desire of our Founder, President George

there are 300 patients currently enrolled, with a

H.W. Bush “was to motivate people to move

External Control Arm

projection of 1,000 by end of 2021. The modules

forward, to look forward, to be ready to do

The first External Control Arm – for small cell lung

of information are based on a meticulous process

things for the future, and that’s exactly what

cancer – has been successfully completed.

of standardization across the research centers, and

the CEO Roundtable on Cancer is doing,”

The program has expanded to address strategies

a set of visualization and analysis tools are in place.

said Andrew Card, Interim CEO of the

and methods for using external data to inform

The existing quality processes for data curation

George & Barbara Bush Foundation.

and data with enhanced socioeconomic content.

decision making at all stages of clinical development, were designed to maximize the impact of the including the use of hybrid and agile study designs.

The pharma industry and FDA continue to have a

registry on regulatory decision-making.

Immune-Related Adverse Events

We want to enhance communities of health,

ambassador for the CEO Roundtable on Cancer

The rapid expansion of immunotherapy for cancer

especially among those disproportionately affected

is Robert J. Brown, CEO & Founder of B&C

Images and Algorithms

has raised the importance and urgency of compiling

by cancer. We will do this by extending the Cancer

Associates, Inc., adviser to past presidents and the

This program is developing state-of-the-art AI

high quality data on immune-related adverse events

Gold Standard to Historically Black Colleges and

Rev. Martin Luther King Jr.

high level of engagement in this program.

algorithms to automate Response Evaluation Criteria (irAEs). PDS has partnered with the ground-

Universities and Hispanic Serving Institutions in

In Solid Tumors (RECIST) reducing inter-radiologist

breaking work of the MGH Severe Immunotherapy

partnership with accredited companies.

variability. The first phase of the program will deliver

Complications Service led by Dr. Kerry Reynolds.

training data sets comprised of more than 1,500

PDS has sponsored the process of standardizing

patient-level CT scans with annotation of all lesions,

definitions and staging of neurologic irAE across a

and the first version of an AI algorithm for liver

broad spectrum of experts; this will be the basis of a

lesions. The program is addressing the automation

registry. A similar effort has begun on dermatologic

of the traditional RECIST protocol (linear measure of

irAEs. 18

There will be focused work to recruit more data to our PDS platform. We have ambitious data sharing

The Cancer Gold Standard accreditation program

goals that will influence policies and best practices

itself is being refreshed and phased in to 50

in clinical trial data transparency. Also, we will

companies per year beginning in 2021. The new

develop data visualization tools that will help

program has greater emphasis on well-being,

investigators to discover hidden patterns in data

diversity and inclusion, health equities and

and draw useful insights for cancer therapies.

advocacy. Joining to support health equity as an

19

CONVENER COLLABORATOR CATALYST

CONVENER COLLABORATOR CATALYST

THE FUTURE

THE FUTURE

PDS research programs are expanding in 2021.

CEORT will be expanding membership beyond the life sciences to other sectors such as Finance and Technology. Expertise from these industries could directly support PDS research programs but also new Cancer Gold Standard criteria looking at additional dimensions of well-being.

Extend registries into new areas: PDS has developed a multi-institutional tumoragnostic registry concept for cancer patients with MET oncogene alterations that will build on our rare tumor registry expertise. We’re also seeking partners as we develop a patient registry for immune-related adverse events and develop an AI-empowered automation framework for curating disease registries.

We have developed External Control Arms

for glioblastoma and small cell

lung cancer from patient-level data from both completed clinical trials and real-world data sources. Over the next three years we will make ECAs for other diseases with high unmet medical need and in consultation with collaborators to support decision-making in all phases of clinical development programs.

Increasing interaction with members

latest thinking and best practices on well-being,

is a priority through a re-energized Life Sciences

health disparities, data sharing and AI applied to

Consortium and creation of a new Health and

measuring tumor progression.

Well-Being Consortium to guide programs like the

For our Images and Algorithms (I&A)

Cancer Gold Standard and new initiatives. Member

program, Phase 2 will automate RECIST 1.1

executives with expertise in these areas are needed

and a measure of total tumor burden. This will be

to guide the programs.

complete in three years and will assess all lesions

Our Annual Meeting will return to November in 2021 Mark your calendar for Nov. 16-17, 2021. Also, another FDA-PDS Symposium is coming in 2021.

Increasing interaction with members also will help

in all organs including liver, lung, and lymph nodes.

20

us to share with employers and researchers the

21

CONVENER COLLABORATOR CATALYST

CONVENER COLLABORATOR CATALYST

THANK YOU

ENGAGE

to our members, accredited Cancer Gold Standard companies, research collaborators, donors and advisors for contributing to these accomplishments, especially in a year of great challenge for everyone!

It is only by working together that we can accomplish the mission set out for us by our founder, President George H.W. Bush.

CONTRIBUTE financially, in-kind, or provide data.

ENGAGE in delivering our new programs or VOLUNTEER as an advisor to one of our programs.

INVITE and ADVOCATE engagement in the CEO Roundtable on Cancer to your colleagues in-house and at other companies.

LEAD by example and earn Gold Standard accreditation.

TAKE ACTION To learn more or get involved, contact: Therese Martin for the CEO Roundtable or Cancer Gold Standard. therese.martin@ceoroundtableoncancer.org Gwen Thomas for Project Data Sphere.

“The CEO Cancer Gold Standard is a powerful

small, for-profit and not-for-profit, to embrace it.

program that advances the elimination of cancer

This is a marvelous example of America’s

as a public health threat. But on a more personal

corporate leadership at its golden best.”

level, it also is a boon to employees and their families. As such, I take great pride in the CEO Roundtable on Cancer that developed the

gwen.thomas@projectdatasphere.org

– President George H.W. Bush 1924-2018

Gold Standard and I urge businesses large and 22

23

www.ceoroundtableoncancer.org